What the Research Shows: Clinical Evidence Summary
Omega Plus provides EPAX® Omega 3-9-11 premium fish oil (1750 mg/2 softgels) delivering 1000 mg EPA and 500 mg DHA (2:1 ratio) plus long-chain monounsaturated omega-9 (gondoic acid) and omega-11 (cetoleic acid) fatty acids from North Atlantic pelagic fish. Note: Individual ingredient RCTs typically evaluate single agents at higher doses than in multi-fatty acid formulas; EPAX-specific data is emerging for the full omega 3-9-11 profile.
*These studies explore outcomes related to individual fatty acids and EPAX formulations used in Omega Plus. Research on individual ingredients does not necessarily reflect the effect of the full formula. When study doses differ from Omega Plus, we note it. Not intended to diagnose, treat, cure, or prevent any disease.
EPAX® Omega 3-9-11 (full profile, 1750 mg/day)
Studied for: skin biophysical function (erythema, barrier integrity) in healthy adults (registered RCT).[ctv.veeva]
Dose note: Protocol specifies low- and high-dose arms (vs placebo) over 12 weeks; results pending. Formula: 1750 mg/day (1000 mg EPA + 500 mg DHA + LC-MUFAs). (ClinicalTrials)
Further reading:
EPAX Omega 3-9-11 skin-function RCT protocol (2022): ClinicalTrials
EPA-dominant Omega-3 (1000 mg EPA + 500 mg DHA, 2:1 ratio)
Studied for: reductions in dysmenorrhea pain intensity, analgesic use, and menstrual-cycle oxidative stress in young women (RCTs and meta-analyses).
Dose note: RCTs use 300–1800 mg/day EPA+DHA over 2–3 months. Formula: 1500 mg/day EPA+DHA. (PubMed)
Further reading:
Rahbar et al., 2012 (RCT, 1 g/day omega-3): PubMed
Snipe et al., 2023 (meta-analysis, 12 RCTs, n=881): Wiley Online
Mano et al., 2022 (RCT, 900 mg EPA + 403 mg DHA ≈2:1, menstrual redox): PMC
EPAX® Cetoleic 10 (omega-11 cetoleic + omega-9 gondoic–rich, pilot RCT data)
Studied for: facial skin redness (inflammation proxy) and Omega-3 Index elevation in healthy adults (randomized placebo-controlled trials).stauberusa+1[ppl-ai-file-upload.s3.amazonaws]
Dose note: 4 g/day in Optihud (n=24 women); CetoIndex equivalent to higher-EPA/DHA oil despite lower EPA/DHA. Formula contributes LC-MUFAs. (ClinicalTrials.gov NCT04768595)
Further reading:
Optihud pilot RCT (Møreforsking, 2022): EPAX Whitepaper
CetoIndex RCT (NCT04768595): ClinicalTrials.gov
Stankova et al., 2018 (uncontrolled, n=100): PubMed
Long-chain omega-11/9 MUFAs (saury oil model, RCT)
Studied for: lipid/lipoprotein profiles (LDL particle number, TG, HDL characteristics) in healthy adults.ncbi.nlm.nih+1
Dose note: 12 g/day saury oil (high C20:1/C22:1 omega-11/9 + 3.4 g EPA+DHA). Formula provides targeted LC-MUFAs. (PMC)
Further reading:
Yang et al., 2020 RCT (crossover, n=30): PMC
Yang et al., 2011 postprandial (n=5): PubMed (wait, wrong; use ) PMC
EPA:DHA ratio effects on inflammation/cardiometabolic markers (meta-regression)
Studied for: CRP reduction favouring higher EPA:DHA ratios (92 RCTs); pure EPA vs DHA differential effects.pubmed.ncbi.nlm.nih+1
Dose note: 0.85–15 g/day EPA+DHA range. (PubMed)
Further reading:
AbuMweis et al., 2021 meta-regression: PubMed
Innes & Calder, 2018 review: PMC
Omega-9 oleic acid (Mediterranean diet/EVOO RCTs) Studied for: cardiovascular risk reduction, metabolic syndrome components in high-risk adults (incl. postmenopausal women). Dose note: Food-based (≥10 g/day EVOO). Formula contributes gondoic (C20:1 n-9). (PubMed) Further reading: Guasch-Ferré et al., PREDIMED (n=7216): PubMed
Med-style diet postmenopausal RCT: ScienceDirect